Welcome to our dedicated page for Oaktree Acquisition III SEC filings (Ticker: OACCW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oaktree Acquisition III's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oaktree Acquisition III's regulatory disclosures and financial reporting.
Oaktree Acquisition Corp. III Life Sciences files its Annual Report outlining its structure and strategy as a Cayman Islands–incorporated, healthcare-focused special purpose acquisition company. It is a blank check company formed in June 2024 to complete an initial business combination.
The company plans to merge with biopharma, medical device, diagnostics or specialized healthcare services businesses in North America, the UK and Western Europe, leveraging its affiliation with Oaktree, which had $223 billion in assets under management as of December 31, 2025. Oaktree’s life sciences platform has committed about $6.2 billion across 54 investments since 2013.
As of December 31, 2025, the SPAC had $201,563,532 available to fund a deal and must complete a business combination within 24 months of its IPO, with potential extensions up to 36 months. The report details sponsor economics, potential conflicts of interest, warrant and share lock-up terms, and the requirement that any target (or targets) have an aggregate fair market value of at least 80% of net assets held in trust at signing.
Oaktree Acquisition Corp I-A received an updated ownership report from Barclays PLC, which filed an amended Schedule 13G/A as of December 31, 2025. Barclays reported beneficial ownership of 861,625 common shares, representing 4.35% of the class.
Barclays reported sole voting and sole dispositive power over all 861,625 shares, with no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report shared beneficial ownership of 803,487 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences, representing 4.1% of the class. Both reporting persons indicate zero sole voting and dispositive power and shared voting and dispositive power of 803,487, showing the stake is held jointly rather than under exclusive control by either entity.
The filing states the securities are held in the ordinary course of business and were not acquired to change or influence control. A joint filing agreement is attached and an exhibit clarifies that The Goldman Sachs Group, Inc. is a parent holding company and Goldman Sachs & Co. LLC is a subsidiary broker-dealer and registered investment adviser. The filing is classified as ownership of 5% or less of the class.
Oaktree Acquisition Corp. III Life Sciences is a blank check company formed to complete a business combination; it has not selected a target. The company completed its Initial Public Offering and private placement and holds $197,576,768 in a Trust Account as of June 30, 2025, intended to fund a Business Combination. For the six months ended June 30, 2025 the company reported $3,533,134 net income, driven by $4,247,746 of interest income on Trust Account funds and offset by $714,612 of general and administrative expenses.
Outside the Trust Account the company had $1,385,359 in cash and $441,907 of working capital. There were 19,199,029 Class A shares subject to possible redemption at a redemption value of $10.29 per share. Material items include a $6,719,660 deferred underwriting fee payable from the Trust Account and sponsor provisions that may require the sponsor to indemnify the Trust Account, although the company notes the sponsor's only assets may be company securities. The company experienced a management change with the CFO resigning and a successor appointed on June 3, 2025.